EX-99.1   

Exhibit 99.1  

HENRY SCHEIN, INC.  

PRO FORMA CONSOLIDATED STATEMENT OF INCOME (UNAUDITED)  

  [DATA_TABLE_REMOVED] 

1   

HENRY SCHEIN, INC.  

PRO FORMA CONSOLIDATED STATEMENT OF INCOME (UNAUDITED)  

  [DATA_TABLE_REMOVED] 

2   

HENRY SCHEIN, INC.  

PRO FORMA CONSOLIDATED STATEMENT OF INCOME (UNAUDITED)  

  [DATA_TABLE_REMOVED] 

3   

HENRY SCHEIN, INC.  

PRO FORMA CONSOLIDATED STATEMENT OF INCOME (UNAUDITED)  

  [DATA_TABLE_REMOVED] 

4   

HENRY SCHEIN, INC.  

PRO FORMA CONSOLIDATED BALANCE SHEET (UNAUDITED)  

  [DATA_TABLE_REMOVED] 

5   

HENRY SCHEIN, INC.  

PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)  

Notes to Pro Forma Consolidated Financial Statements (Unaudited)  

The unaudited pro forma consolidated statements of income for the nine months ended September 29, 2018 and for the year ended December 30, 2017 and the unaudited pro forma consolidated balance sheet as of September 29, 2018, include the following pro forma adjustments:  

   (A)  

Reflects the removal of all non-recurring transaction costs related to the previously announced separation of Henry Schein, Inc.’s (the “Company”) Animal Health business (the “Henry Schein Animal Health Business”) (the “Separation”) which were incurred by the Company during the nine months ended September 29, 2018. These costs were primarily for tax, information technology, advisory fees, and other professional services.  

   (B)  

Reflects a reduction in interest expense in connection with debt securities expected to be repaid by the Company in February 2019 using the proceeds from the Separation and related transactions. The interest adjustment is based on the historical interest expense associated with the borrowings to be repaid upon Separation and related transactions.  

   (C)  

Adjusted to reflect the income tax effects of the pro forma adjustments at the applicable statutory tax rates.  

   (D)  

Represents the adjustment for the repayment of debt from the net proceeds of the distribution of $1,120.0 million from Covetrus, Inc., a wholly owned subsidiary of the Company prior to the Separation (“Covetrus”) incurred in connection with a debt financing by Covetrus, the issuance of $361.1 million of shares of Covetrus common stock to certain institutional accredited investors in connection with the Separation and the merger with Direct Vet Marketing, Inc. (d/b/a Vets First Choice) (“Vets First Choice”) , $14.0 million related to the sale of two business units associated with the Separation and related transactions, offset by $73.3 million related to the buyout of certain minority interests in connection with the Separation and related transactions.  

6